CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.
Per age group per patient year
*There were no infections per patient-year in patients aged 2 to <5 years (95% CI, 0.00-4.61). In patients 5 to <12 years, there were 1.72 infections per patient-year (95% CI, 0.85-3.05), and in patients 12 to <16 years, there were 2.00 infections per patient-year (95% CI, 0.70-4.35).
†There were no days off of school per patient-year in patients aged 2 to <5 years (95% CI, 0.00-4.61). In patients 5 to <12 years, there were 0.96 days missed (95% CI, 0.35-2.06), and in patients 12 to <16 years, there were 1.86 days missed (95% CI, 0.21-6.61).
‡There were no hospitalizations per patient-year in patients aged 2 to <5 years (95% CI, 0.00-4.61), patients aged 5 to <12 years (95% CI, 0.00-0.32), and patients aged 12 to <16 years (95% CI, 0.00-0.66).
Click to see Study Design above.
Review Important Safety Information, including contraindications and other specific warnings and precautions to consider when prescribing and monitoring patients treated with CUVITRU.
See how CUVITRU provides patients options.
References